Abstract
We aimed to determine if changes in the patterns of upper gastrointestinal diseases at endoscopy have occurred over the past decade. Retrospectively, 917 consecutive patients were selected based on upper endoscopy between June 1 and August 31, in 1990 (n = 217), 1994 (n = 270), and 1998 (n = 430). Demographic, clinical, endoscopic, and histological information were extracted from the medical records on a standardized case record form. Over the eight-year period, follow-up of peptic ulcer (15%, 5%, and 5%, respectively, in 1990, 1994, and 1998, df = 2, P < 0.001), bleeding (22%, 14%, and 13%, P = 0.008), and nausea/vomiting (15%, 16%, and 10%, df = 2, P = 0.003) had become less frequent, but reflux (21%, 19%, and 34%, df = 2, P < 0.001) and dyspepsia (24%, 43%, and 32%, df = 2, P < 0.001) more frequent indications for upper endoscopy. The prevalence of peptic ulcer disease decreased (22%, 15%, and 13%, df = 2, P = 0.025), but the prevalence of reflux esophagitis increased significantly (29%, 30%, and 39%, df = 2, P = 0.010). The prevalence of both the use of nonsteroidal antiinflammatory drugs (NSAIDs) (18%, 20%, and 11%, respectively, in 1990, 1994, and 1998, df = 2, P = 0.004) and H. pylori infection (39% in 1994 and 30% in 1998, df = 1, P = 0.032) decreased. Overall, NSAID use was independently associated with gastric ulcers (OR = 2.39, 95% CI 1.21–4.73, χ2 = 6.31, df = 1, P = 0.012), but not esophagitis. H. pylori infection was independently associated with duodenal ulcers (OR = 4.74, 95% CI 2.30–9.77, χ2 = 17.8, df = 1, P < 0.001), histologically chronic (OR = 166.8, 95% CI 76.1–365.4, χ2 = 313.0, df = 1, P < 0.001) and active (OR = 30.1, 95% CI 17.0–53.5, χ2 = 189.7, df = 1, P < 0.001) gastritis and lymphoid aggregates (OR = 5.49, 95% CI 3.02–9.97, χ2 = 36.3, df = 1, P < 0.001). In conclusion, the prevalence of peptic ulcer disease appears to have been decreasing, whereas reflux esophagitis has been increasing over the past decade in Western Sydney. The decreased use of NSAIDs and decline of H. pylori infection have likely both contributed to the reduction of peptic ulcer disease, but the increase in reflux esophagitis remains to be fully explained.
Similar content being viewed by others
References
Locke GR III, Talley NJ, Fett SL, Zinsmeister AR, Melton LJ III: Prevalence and clinical spectrum of gastroesophageal re-flux: A population-based study in Olmsted county, Minnesota. Gastroenterology 112:1448–1456, 1997
Revicki DA, Wood M, Maton PN, Sorensen S: The impact of gastroesophageal reflux disease on quality of life. Am J Med 104:252–258, 1998
Jensen DM: Economic and health aspects of peptic ulcer disease and H2-receptor antagonists. Am J Med 81:42–48, 1986
Wilhelmsen I, Berstad A: Quality of life and relapse of duodenal ulcer before and after eradication of Helicobacter pylori. Scand J Gastroenterol 29:874–879, 1994.
Marshall, BJ: Unidentified curved bacilli on gastric epithelium in active chronic gastritis. Lancet i:1273–275, 1983
Consensus Development Panel on Helicobacter pylori in Peptic Ulcer Disease: Helicobacter pylori in peptic ulcer disease. JAMA 272:65–69, 1994
International Agency for Research on Cancer: Schistosomes, liver flukes and Helicobacter pylori. In IARC Monographs on the Evaluation of Carcinogenic Risks to Humans. IARC Monograph, Vol 61. Lyon, IARC, 1994, pp. 177–241
Watanabe T, Tada M, Nagai H, Sasaki S, Nakao M: Helicobacter pylori infection induces gastric cancer in Mongolian gerbils. Gastroenterology 115:642–648, 1998
Eslick GD, Lim L L-Y, Byles JE, Xia H H-X, Talley NJ: Association of Helicobacter pylori infection with gastric carcinoma: a meta-analysis. Am J Gastroenterol 94:2373–1379, 1999
Xia H H-X, Talley NJ: Prospects for improved therapy for Helicobacter pylori infection. Exp Opin Invest Drugs 5:959–976, 1996
Lam SK, Talley NJ: Helicobacter pylori consensus. Report of the 1997 Asia Pacific Consensus Conference on the management of Helicobacter pylori infection. J Gastroenterol Hepatol 13:1–12, 1998
Xia HH-X, Talley NJ: Helicobacter pylori eradication in patients with non-ulcer dyspepsia. Drugs 58:785–792, 1999
Xia HH-X, Kalantar J, Talley NJ, Ma Wyatt J, Adams S, Cheung K: Antral-type mucosa in the gastric incisura (antralization)– a link between Helicobacter pylori infection and intestinal metaplasia? Am J Gastroenterol 95:114–121, 2000
Borody TJ, Andrews P, Jankiewicz E, et al: Apparent reversal of early gastric mucosal atrophy after triple therapy for Helicobacter pylori. Am J Gastroenterol 88:1266–1268, 1993
Forbes GM, Warren JR, Glaser ME, Cullen DJ, Marshall BJ, Collins BJ: Long-term follow-up of gastric histology after Helicobacter pylori eradication. J Gastroenterol Hepatol 112:670–673, 1996
Tucci A, Poli L, Tosetti C, Biasco G, et al: Reversal of fundic atrophy after eradication of Helicobacter pylori. Am J Gastroenterol 93:1425–1431, 1998
Annibale B, Rosaria Aprile M, S'Ambra G, Caruana P, Bordi C, Delle Fave G: Cure of Helicobacter pylori infection in atrophic body gastritis patients does not improve mucosal atrophy but reduces hypergastrinemia and its related effects on body ECL-cell hyperplasia. Aliment Pharmacol Ther 14:625–634, 2000
Xia HH-X, Talley NJ: Helicobacter pylori infection, atrophic gastritis and reflux esophagitis: An unexplored triangle. Am J Gastroenterol 93:394–400, 1998
O'Connor HJ: Helicobacter pylori and reflux gastro-oesophageal disease–clinical implications and management. Aliment Pharmacol Ther 13:117–1127, 1999
Fallone CA, Barkun AN, Friedman G, et al: Is Helicobacter pylori eradication associated with gastroesophageal reflux disease? Am J Gastroenterol 95:914–920, 2000
Hamada H, Haruma K, Mihara M, et al: High incidence of reflux oesophagitis after eradication therapy for Helicobacter pylori: Impacts of hiatal hernia and corpus gastritis. Aliment Pharmacol Ther 14:729–735, 2000
Haruma K, Hamada H, Mihara M, et al: Negative association between Helicobacter pylori infection and reflux esophagitis in older patients: Case-control study in Japan. Helicobacter 5:24–29, 2000
Wu JCY, Sung JJ, Ng EKW, et al: Prevalence and distribution of Helicobacter pylori in gastroesophageal reflux disease: A study from the East. Am J Gastroenterol 94:1790–1794, 1999
Metz DC, Kroser JA: Helicobacter pylori and gastroesophageal reflux disease. Gastroenterol Clin North Am 28:871–885, 1999
Talley NJ, Janssens J, Lauritsen K, et al: No increase of reflux symptoms or esophagitis in patients with non-ulcer dyspepsia 12 months after Helicobacter pylori eradication. A randomized double-blind placebo-controlled trial. Gastroenterology 114:A306, 1998 (abstract)
Vakil N, Hahn B, McSorley D: Recurrent symptoms and gastro-oesophageal reflux disease in patients with duodenal ulcer treated for Helicobacter pylori infection. Aliment Pharmacol Ther 14:45–51, 2000
Bytzer P, Havelund T, Moller Hansen J: Interobserver variation in the endoscopic diagnosis of reflux esophagitis. Scand J Gastroenterol 28:119–125, 1993
Armstrong D, Bennett JR, Blum AL, et al: The endoscopic assessment of esophagitis: A progress report on observer agreement. Gastroenterology 111:85–92, 1996
Dixon MF, Genta RM, Yardley JH, Correa P, the participants in the International Workshop on the Histopathology of Gastritis, Houston 1994: Classification and grading of gastritis. The updated Sydney system. Am J Surg Pathol 20:1161–1181, 1996
Marshall BJ, Warren JR, Francis GJ, Langton SR, Goodwin CS, Blincow ED: Rapid urease test in the management of Campylobacter pyloridis-associated gastritis. Am J Gastroenterol 82:200–210, 1987
Kalantar J, Xia HH-X, Ma Wyatt J, Rose D, Talley NJ: Determination of optimal biopsy sites for detection of H. pylori in patients treated or not treated with antibiotic and antisecretory drugs. Gastroenterology 112:A165, 1997, (abstract)
Xia HH-X, Kalantar JS, Ma Wyatt J, et al: High sensitivity and specificity of a laboratory-based serological test, pylori DTect ELISA, for detection of Helicobacter pylori infection. Diag Microbiol Infect Dis 36:69–74, 2000
Xia HH-X, Kalantar JS, Mitchell HM, Talley NJ: Can Helicobacter pylori serology still be applied as a surrogate marker to identify peptic ulcer disease in dyspepsia? Aliment Pharmacol Ther 15:615–624, 2000
Marshall BJ, Warren JR: Unidentified curved bacilli in the stomach of patients with gastritis and peptic ulceration. Lancet 1:1311–1315, 1984
Marshall BJ, McGechie DB, Rogers PA, Glancy RJ: Pyloric Campylobacter infection and gastroduodenal disease. Med J Aust 142:439–443, 1985
Lambert JR, Dunn KL, Eaves ER, Korman MG, Hansky J, Pinkard KJ: Pylori CLO in the human stomach. Med J Aust 143:174, 1985 (letter)
McManus P, Henry DA, Birkett DJ: Recent changes in the profile of prescription NSAID use in Australia. Med J Aust 172:188, 2000 (letter)
Henry A, Batey RG: Low prevalence of Helicobacter pylori in an Australian duodenal ulcer population: NSAIDitis or the effect of ten years of H. pylori treatment? Aust NZ J Med 28:345, 1998 (letter)
Nandurkar S, Talley NJ, Martin CJ, Ng THK, Adams S: Short segment Barrett' oesophagus: Prevalence, diagnosis and associations. Gut 40:710–715, 1997
Nandurkar S, Talley NJ: Barrett' oesophagus: The long and the short of it. Am J Gastroenterol 94:30–40, 1999
Xia HH-X, Talley NJ: Natural acquisition and spontaneous elimination of Helicobacter pylori infection. Am J Gastroenterol 92:1780–1787, 1997
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Xia, H.HX., Phung, N., Altiparmak, E. et al. Reduction of Peptic Ulcer Disease and Helicobacter pylori Infection but Increase of Reflux Esophagitis in Western Sydney Between 1990 and 1998. Dig Dis Sci 46, 2716–2723 (2001). https://doi.org/10.1023/A:1012731614075
Issue Date:
DOI: https://doi.org/10.1023/A:1012731614075